X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
afatinib (319) 319
humans (255) 255
index medicus (235) 235
oncology (161) 161
gefitinib (140) 140
lung neoplasms - drug therapy (138) 138
mutation (127) 127
erlotinib (114) 114
pharmacology & pharmacy (114) 114
female (112) 112
carcinoma, non-small-cell lung - drug therapy (100) 100
quinazolines - pharmacology (100) 100
protein kinase inhibitors - pharmacology (99) 99
open-label (98) 98
chemotherapy (97) 97
antineoplastic agents - pharmacology (89) 89
egfr (86) 86
cell line, tumor (84) 84
lung neoplasms - genetics (82) 82
male (80) 80
animals (78) 78
cancer (77) 77
antineoplastic agents - therapeutic use (74) 74
epidermal growth factor (74) 74
lung cancer (72) 72
quinazolines - therapeutic use (72) 72
lung cancer, non-small cell (70) 70
protein kinase inhibitors - therapeutic use (70) 70
lung neoplasms - pathology (68) 68
1st-line treatment (67) 67
acquired-resistance (67) 67
middle aged (63) 63
cell lung-cancer (62) 62
aged (60) 60
carcinoma, non-small-cell lung - genetics (60) 60
receptor, epidermal growth factor - genetics (59) 59
tyrosine (58) 58
adenocarcinoma (54) 54
receptor, epidermal growth factor - antagonists & inhibitors (53) 53
tyrosine kinase inhibitors (52) 52
growth-factor receptor (51) 51
erbb receptors - genetics (50) 50
tyrosine kinase inhibitor (48) 48
carcinoma, non-small-cell lung - pathology (46) 46
erbb receptors - antagonists & inhibitors (45) 45
mice (45) 45
drug resistance, neoplasm (43) 43
analysis (42) 42
non-small cell lung cancer (42) 42
adult (41) 41
care and treatment (40) 40
nsclc (40) 40
respiratory tract diseases (39) 39
xenograft model antitumor assays (39) 39
bibw 2992 (38) 38
quinazolines - administration & dosage (37) 37
research (37) 37
genetic aspects (36) 36
kinases (36) 36
treatment outcome (36) 36
epidermal growth factor receptor (35) 35
medicine & public health (35) 35
pharmacokinetics (34) 34
egfr mutations (33) 33
epidermal growth factor receptors (33) 33
erbb family blocker (33) 33
health aspects (33) 33
lung neoplasms - metabolism (33) 33
adenocarcinoma - drug therapy (32) 32
adenocarcinoma of lung (31) 31
article (31) 31
therapy (31) 31
antineoplastic agents - adverse effects (30) 30
drug therapy (30) 30
erbb receptors - metabolism (30) 30
pharmacology/toxicology (30) 30
protein-tyrosine kinase (30) 30
resistance (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
mutations (29) 29
quinazolines - adverse effects (29) 29
non-small cell lung carcinoma (28) 28
tumors (28) 28
clinical trials (27) 27
egfr mutation (27) 27
lung-cancer (27) 27
aged, 80 and over (26) 26
drug resistance, neoplasm - genetics (26) 26
mice, nude (26) 26
receptor, epidermal growth factor - metabolism (26) 26
cancer research (25) 25
cancer therapies (25) 25
inhibitors (25) 25
lung neoplasms - enzymology (25) 25
metastasis (25) 25
cell proliferation - drug effects (24) 24
patients (24) 24
signal transduction - drug effects (24) 24
trial (24) 24
disease-free survival (23) 23
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Communications, ISSN 2041-1723, 03/2017, Volume 8, Issue 1, p. 14768
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2016, Volume 22, Issue 20, pp. 5130 - 5140
Journal Article
Nature Communications, ISSN 2041-1723, 2015, Volume 6, Issue 1, p. 6377
Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However,... 
GROWTH-FACTOR RECEPTOR | DRUG-SENSITIVITY | GEFITINIB | AMPLIFICATION | MODELS | GENE | MULTIDISCIPLINARY SCIENCES | MUTATION | ACQUIRED-RESISTANCE | KINASE INHIBITORS | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Recurrence | Adenocarcinoma - pathology | Adenocarcinoma of Lung | Humans | Lung Neoplasms - metabolism | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | bcl-X Protein - genetics | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Small Cell Lung Carcinoma - metabolism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Adenocarcinoma - metabolism | Adenocarcinoma - genetics | Antineoplastic Agents - pharmacology | Lung - metabolism | Gefitinib | ErbB Receptors - deficiency | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung - pathology | Aniline Compounds - pharmacology | ErbB Receptors - antagonists & inhibitors | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Retinoblastoma Protein - deficiency | Small Cell Lung Carcinoma - genetics | Sulfonamides - pharmacology | Adenocarcinoma - drug therapy | Disease Progression | Drug Resistance, Neoplasm - genetics | Small Cell Lung Carcinoma - pathology | Afatinib | Retinoblastoma Protein - genetics | Erlotinib Hydrochloride - pharmacology | Lung - drug effects | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Quinazolines - pharmacology | bcl-X Protein - metabolism | Proto-Oncogene Proteins c-bcl-2 - genetics | Drug Resistance, Neoplasm - drug effects
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 09/2018, Volume 158, pp. 174 - 183
A new method for the quantitative analysis by liquid chromatography-tandem mass spectrometry (LC–MS/MS) of five tyrosine kinase inhibitors (afatinib,... 
Therapeutic drug monitoring | Tyrosine kinase inhibitor | LC–MS/MS | Lung cancer | TYROSINE KINASE INHIBITORS | LC-MS/MS | CHEMISTRY, ANALYTICAL | METABOLITES | MOUSE PLASMA | PHARMACOKINETICS | QUANTIFICATION | UPLC-MS/MS | PHARMACOLOGY & PHARMACY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Chromatography, High Pressure Liquid | Drug Monitoring - methods | Tandem Mass Spectrometry | Pyrazoles - blood | Sensitivity and Specificity | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Piperazines - blood | Pyrazoles - pharmacology | Pyridines - therapeutic use | Crizotinib | Limit of Detection | Reproducibility of Results | ErbB Receptors - antagonists & inhibitors | Drug Stability | Indoles - blood | Piperazines - therapeutic use | Piperazines - pharmacology | Protein Kinase Inhibitors - blood | Quinazolines - blood | Erlotinib Hydrochloride - blood | Pyridines - blood | Afatinib | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Erlotinib Hydrochloride - pharmacology | Antineoplastic Agents - blood | Carcinoma, Non-Small-Cell Lung - blood | Indoles - therapeutic use | Erlotinib Hydrochloride - therapeutic use | Lung Neoplasms - blood | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - pharmacology | Tyrosine | Lung cancer, Small cell | Liquid chromatography | Lung cancer, Non-small cell | Antineoplastic agents | Antimitotic agents | Epidermal growth factor | Erlotinib | Analysis | Formic acid | Nitriles | Lymphomas | Precipitation (Meteorology) | Health aspects | Mass spectrometry | Vascular endothelial growth factor
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 6, pp. 770 - 780
Abstract Although anti-HER2 (human epidermal growth factor receptor 2) therapy is currently approved for breast, gastric, and gastroesophageal cancers... 
Hematology, Oncology and Palliative Medicine | Human epidermal growth factor 2 | Pertuzumab | Afatinib | Target therapy | Lapatinib | Ado-trastuzumab emtansine | Trastuzumab | Cancer | GYNECOLOGIC-ONCOLOGY-GROUP | IN-SITU HYBRIDIZATION | UROTHELIAL BLADDER-CANCER | CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | SALIVARY DUCT CARCINOMA | ONCOLOGY | METASTATIC BREAST-CANCER | AFATINIB BIBW 2992 | GENE AMPLIFICATION | Neoplasms - metabolism | Up-Regulation | Receptor, ErbB-2 - genetics | Humans | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Male | Uterine Cervical Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Maytansine - pharmacology | Breast Neoplasms - metabolism | Peritoneal Neoplasms - drug therapy | Uterine Cervical Neoplasms - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Adult | Female | Antineoplastic Agents - pharmacology | Molecular Targeted Therapy - methods | Peritoneal Neoplasms - secondary | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Uterine Cervical Neoplasms - drug therapy | Clinical Trials as Topic | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Animals | Gene Amplification | Quinazolines - therapeutic use | Peritoneal Neoplasms - metabolism | Protein Kinase Inhibitors - pharmacology | Mutation | Quinazolines - pharmacology | Care and treatment | Biological products | Epidermal growth factor | Lung cancer, Non-small cell | Health aspects
Journal Article
Cancer Science, ISSN 1347-9032, 10/2015, Volume 106, Issue 10, pp. 1377 - 1384
Afatinib is an irreversible epidermal growth factor receptor ( EGFR )‐tyrosine kinase inhibitor ( TKI ) that is known to be effective against the EGFR T790M... 
TKI | cancer stem cells | drug resistance | Afatinib | EGFR | non‐small cell lung cancer | EGFR-TKI | Cancer stem cells | Drug resistance | Non-small cell lung cancer | non-small cell lung cancer | EGFR INHIBITORS | MET AMPLIFICATION | ONCOLOGY | ADENOCARCINOMA | MUTATIONS | GEFITINIB RESISTANCE | ERLOTINIB | Cell Proliferation | Taxoids - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Aldehyde Dehydrogenase - biosynthesis | Drug Resistance, Neoplasm | Epithelial-Mesenchymal Transition - drug effects | Lung Neoplasms - pathology | Base Sequence | Neoplastic Stem Cells - pathology | Female | Antineoplastic Agents - pharmacology | Pyrazoles - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | DNA Methylation - genetics | Mice, SCID | Sequence Analysis, DNA | Animals | Mutation - drug effects | ATP Binding Cassette Transporter, Sub-Family B - biosynthesis | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice, Inbred NOD | Mice | MicroRNAs - genetics | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Quinazolines - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors | Epigenetic inheritance | Tyrosine | Immunoglobulins | Epidermal growth factor receptors | Mesenchyme | Laboratories | Lung cancer | Kinases | c-Met protein | Epidermal growth factor | Hospitals | Medical prognosis | Cell lines | Stem cells | Mutation | Protein-tyrosine kinase | Original
Journal Article
Journal Article